ACADIA Pharmaceuticals Inc. (ACAD) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 37 analysts55.7% Below Target
ACAD trades 55.7% below Wall Street's consensus target of $33.67.
Current Price$21.62
Average Target$33.67
Target
Current
Low$29.00
Median$33.50
High$40.00
Analyst Target Range
Forward P/E55.6x
(High Premium)
PEG Ratio—
Implied Growth-82.1%
(Declining)
Analyst Spread32.7%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ACAD achieves its forward estimates and maintains a stable P/E multiple of 55.6x. This scenario reflects the blended consensus of 37 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ACAD Price Target Analysis
Updated June 20, 2026As of June 20, 2026, ACADIA Pharmaceuticals Inc. (ACAD) has a Wall Street consensus price target of $33.67, based on estimates from 37 covering analysts. With the stock currently trading at $21.62, this represents a potential upside of +55.7%. The company has a market capitalization of $3.70B.
Analyst price targets range from a low of $29.00 to a high of $40.00, representing a 33% spread in expectations. The median target of $33.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACAD trades at a trailing P/E of 9.4x and forward P/E of 55.6x. Analysts expect EPS to grow -82.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $8.54, with bear and bull scenarios of $5.38 and $11.26 respectively. Model confidence stands at 57/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+48.6%
Industry Consensus
Avg Forward P/E
22.8x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 AXSMAxsome Therapeutics, Inc. | $12.9B | $250.50 | $262.38 | +4.7% | Buy | — | 26 |
 INTRInter & Co, Inc. | $2.4B | $5.44 | $9.40 | +72.8% | Buy | 1.3x | 6 |
 PTCTPTC Therapeutics, Inc. | $6.6B | $78.98 | $95.83 | +21.3% | Buy | 89.1x | 26 |
 BIIBBiogen Inc. | $29.0B | $196.58 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 ALKSAlkermes plc | $7.5B | $44.99 | $49.50 | +10.0% | Buy | — | 28 |
 SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.38 | $60.00 | +35.2% | Buy | 17.8x | 14 |
 JAZZJazz Pharmaceuticals plc | $14.1B | $224.66 | $257.44 | +14.6% | Buy | 8.9x | 48 |
 NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
ACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
What is the ACAD stock price target for 2026?
The consensus Wall Street price target for ACAD is $33.67, representing 55.7% upside from the current price of $21.62. With 37 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ACAD a buy, sell, or hold?
ACAD has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $33.67 implies 55.7% upside from current levels.
Is ACAD stock overvalued or undervalued?
At a forward P/E of 55.5641x, ACAD trades at a premium valuation. The consensus price target of $33.67 (55.7% upside) suggests analysts still see growth justifying the multiple.
How high can ACAD stock go?
The most bullish Wall Street analyst has a price target of $40 for ACAD, while the most conservative target is $29. The consensus of $33.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $11 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover ACAD stock?
ACAD is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 10 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ACAD stock forecast?
The 12-month ACAD stock forecast based on 37 Wall Street analysts shows a consensus price target of $33.67, with estimates ranging from $29 (bear case) to $40 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $5/$11.
What is ACAD's fair value based on fundamentals?
Our quantitative valuation model calculates ACAD's fair value at $9 (base case), with a bear case of $5 and bull case of $11. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 57/100.
What is ACAD's forward P/E ratio?
ACAD trades at a forward P/E ratio of 55.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 9.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ACAD stock?
Wall Street analysts are very optimistic on ACAD, with a "Buy" consensus rating and $33.67 price target (55.7% upside). 26 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ACAD price targets vary so much?
ACAD analyst price targets range from $29 to $40, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.67 consensus represents the middle ground. Our model's $5-$11 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare